Phase 3 N=305 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis
Psoriasis
Primary: Overall Disease Severity Success (ODS) — 100.0; 84.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=150 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
Restless Legs Syndrome
Primary: Change From Baseline To The End Of The Maintenance Period in International Restless Legs Scale (IRLS) Sum Score — -15.46; -15.19 units on a scale — p=0.8451
Phase 3 N=1,237 Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand
Infections, Papillomavirus
Primary: Number of Subjects With Any, Grade 3 and Related Serious Adverse Events (SAEs) — 11; 1; 0; 1 Subjects
Phase 3 N=58 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
Familial Adenomatous Polyposis Coli · FAP
Primary: Absolute Change in the Number of Polyps Measured in a Focal Area of the Rectum. — -0.5; 0.5 Change from baseline number of polyps. — p=0.005
Phase 3 N=35 Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
Fabry Disease
Primary: Change From Baseline in Left Ventricular Mass Indexed to Height (LVMI) — -0.75 g/m^2.7
Phase 3 N=416 Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=0.0001
Phase 3 N=390 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Binge Eating Disorder
Primary: Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12 — -2.26; -3.92 Binge days per week — p=<0.001
Phase 3 N=300 The Kiva® System as a Vertebral Augmentation Treatment
Spinal Fractures · Fractures, Compression · Back Injuries
Primary: Proportion of Participants With Study Success — 120; 123 participants
Phase 3 N=1,509 A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate) — 39.0; 38.1 Percentage of participants
Phase 3 N=405 Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=<0.0001
Phase 3 N=508 LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
Breast Neoplasms
Primary: Progression-free Survival (PFS) — 5.49; 5.55 Months — p=0.4224
Phase 3 N=111 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL)…
Phase 3 N=538 Smoking-Cessation and Stimulant Treatment (S-CAST)
Cocaine Dependence · Methamphetamine Dependence · Nicotine Dependence
Primary: Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens — 77.7; 78.0 percentage of weeks
Phase 3 N=108 A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment
Luteal Hormone Supplementation
Primary: The Proportion of Subjects With Blood Progesterone Concentration Not Less Than 10 ng/ml — 98.9 percentage of subjects
Phase 3 N=104 Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)
Hypertension · Heart Failure
Primary: Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes — 15.0; NA Minutes